Sanofi Genzyme
Sanofi Genzyme is Sanofi's specialty care division developing and commercializing treatments for rare diseases, multiple sclerosis, oncology, and immunology, including enzyme replacement therapies such as imiglucerase and the late-stage MS candidate tolebrutinib.
- Company typePrivate
- Founded2011
- HeadquartersCambridge, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sanofi Genzyme does
Sanofi Genzyme is the specialty care division of Sanofi S.A., formed when Sanofi acquired Genzyme Corporation in 2011. The division develops and commercializes treatments for rare genetic diseases, multiple sclerosis, oncology, and immunology, serving patient populations with high unmet medical needs across rare lysosomal storage disorders, hemophilia A, neuroimmunological conditions, and rare immunology indications. Its therapeutic portfolio is anchored by enzyme replacement therapies such as imiglucerase for Gaucher disease and a late-stage pipeline candidate, tolebrutinib — a BTK inhibitor for multiple sclerosis that has received FDA Breakthrough Therapy Designation and is identified in Clarivate's 2026 Drugs to Watch report.
Underlying the portfolio are platform capabilities in gene therapy, RNAi, and precision biologics, supported by orphan-drug regulatory protections and Sanofi's global R&D and manufacturing scale. The division employs 5,001-10,000 staff, with its U.S. headquarters in Cambridge, Massachusetts, and operates as one of four "power centers" in rare disease pharmaceuticals alongside AstraZeneca/Alexion, Novartis, Pfizer, and Roche. Sanofi Genzyme's go-to-market relies on premium pricing enabled by orphan-drug exclusivity, specialty distribution, and increasingly on policy-led access programs such as the Maharashtra (India) state health insurance reserve covering nine rare disease treatments.
Revenue is generated through the commercialization of approved specialty care products and the development of pipeline assets, supplemented by inorganic growth via acquisitions such as Blueprint Medicines Corporation (2025), which expanded the rare immunology footprint. Specific segment-level revenue is not publicly disclosed; financial performance is reported within Sanofi S.A.'s consolidated specialty care results.
Sanofi Genzyme firmographics
Firmographics- Name
- Sanofi Genzyme
- Legal name
- Sanofi
- Website
- https://sanofigenzyme.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Sanofi Genzyme is Sanofi's specialty care division developing and commercializing treatments for rare diseases, multiple sclerosis, oncology, and immunology, including enzyme replacement therapies such as imiglucerase and the late-stage MS candidate tolebrutinib.
- Ownership category
- akta.pro rank
Sanofi Genzyme industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
- akta.pro secondary industries
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Sanofi Genzyme is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Sanofi Genzyme business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Sanofi Genzyme product offering
Product offeringCore offering
Sanofi Genzyme develops, manufactures, and commercializes specialty care biopharmaceutical therapies for rare diseases (e.g., Gaucher disease, Fabry disease, lysosomal storage disorders), multiple sclerosis, oncology, immunology, and rare blood disorders (hemophilia). The division sells enzyme replacement therapies, recombinant clotting factors, and advanced biologics globally through Sanofi's pharmaceutical distribution network.
Product overview
Sanofi Genzyme operates as Sanofi's specialty care division, focused on rare diseases, rare blood disorders, immunology, neurology, and oncology. The company offers enzyme replacement therapies such as imiglucerase for Gaucher disease, while advancing pipeline candidates like tolebrutinib for multiple sclerosis. Sanofi's broader portfolio spans specialty care focus areas (Immunology, Neurology, Oncology, Rare Blood Disorders, Rare Diseases) and general medicine (Cardiovascular Diseases, Diabetes, Transplant), with additional expertise in vaccines and infectious disease prevention.
Differentiator
Problem solved
Functional benefit
Products and services
- Imiglucerase Enzyme replacement therapy used in the treatment of Gaucher disease, a rare genetic lysosomal storage disorder, for patients with limited treatment options.
- Tolebrutinib Investigational oral BTK inhibitor being developed for the treatment of multiple sclerosis and other neuroimmunological conditions.
Quantifiable outcome
- Tolebrutinib received FDA Breakthrough Therapy Designation for multiple sclerosis
- +1 more outcomes
Companies that use Sanofi Genzyme
Customer profileSegments5 records
Ideal customer profiles3 records
Sanofi Genzyme technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sanofi Genzyme partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Blueprint Medicines CorporationcoreSanofi acquired Blueprint Medicines Corporation for rare immunology medicines, strengthening its rare disease portfolio and immunology pipeline.
- Maharashtra Cabinet (India)minorMaharashtra cabinet approved state health insurance reserve funds for nine rare disease treatments exceeding INR 0.5 million, improving patient access to treatments in India.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
Sanofi Genzyme competitors and assessment
Company assessmentDirect peers
- Alexion (AstraZeneca Rare Disease): Alexion is AstraZeneca's rare disease unit and the most direct competitor to Sanofi Genzyme, operating in the same orphan-drug space (e.g., lysosomal storage disorders, rare hematology, rare nephrology) with comparable regulatory incentives and premium pricing models.
- BioMarin Pharmaceutical: BioMarin is a pure-play rare disease biotech focused on enzyme replacement therapies and gene therapies for genetic conditions including lysosomal storage disorders, directly overlapping Sanofi Genzyme's core franchise.
- Vertex Pharmaceuticals: Vertex is a leading rare disease biotech with franchises in cystic fibrosis and emerging sickle cell/gene therapy programs, competing for share of the high-value orphan drug market that Sanofi Genzyme addresses.
- Regeneron Pharmaceuticals: Regeneron is a leading biotech with strong antibody-based biologics capabilities (Eylea, Dupixent via Sanofi partnership) overlapping with Sanofi Genzyme's specialty biologics and rare immunology pipeline.
Broad incumbents
- Novartis: Novartis is a broad pharmaceutical incumbent with significant rare disease exposure (including gene therapy via AveXis/Zolgensma) and multiple sclerosis franchises that overlap with Sanofi Genzyme's specialty care portfolio.
- Roche: Roche is a broad incumbent with rare disease, neurology (MS via Ocrevus), and biologics capabilities that compete across multiple Sanofi Genzyme therapeutic areas including rare hematology and immunology.
- Pfizer: Pfizer is a broad incumbent with a substantial rare disease franchise built around hematology (hemophilia), rare cardiology, and rare endocrinology, directly competing with Sanofi Genzyme across several core indications.
- Takeda Pharmaceutical: Takeda is a global pharma incumbent with deep rare disease and rare hematology exposure via its Shire acquisition, with overlapping franchises in lysosomal storage disorders and hemophilia that compete with Sanofi Genzyme.
- Amgen: Amgen is a broad incumbent biotech with rare disease exposure (e.g., rare hematology, bone disorders) and biologics manufacturing capabilities that overlap with Sanofi Genzyme's specialty care portfolio.
Emerging players
- Ultragenyx Pharmaceutical: Ultragenyx is an emerging rare disease biotech focused on novel therapies for genetic and ultra-rare diseases, including enzyme replacement and gene therapy candidates that overlap with Sanofi Genzyme's lysosomal storage disorder pipeline.
Market position
Strengths5 records
Weaknesses2 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Sanofi Genzyme social profiles
Digital presenceSanofi Genzyme financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanofi Genzyme leadership team
Management profileNumber of profiles
Profiles6 records
Sanofi Genzyme funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanofi Genzyme M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanofi Genzyme
What does Sanofi Genzyme do?
Sanofi Genzyme develops, manufactures, and commercializes specialty care biopharmaceutical therapies for rare diseases (e.g., Gaucher disease, Fabry disease, lysosomal storage disorders), multiple sclerosis, oncology, immunology, and rare blood disorders (hemophilia). The division sells enzyme replacement therapies, recombinant clotting factors, and advanced biologics globally through Sanofi's pharmaceutical distribution network.
Is Sanofi Genzyme a public or private company?
Sanofi Genzyme is a private company. It is classified as corporate owned and is currently operating.
When was Sanofi Genzyme founded?
Sanofi Genzyme was founded in 2011. It employs 5,001 to 10,000 people.
Where is Sanofi Genzyme based?
Sanofi Genzyme is headquartered in Cambridge, United States, in the North America region.
Who are Sanofi Genzyme's main competitors?
Direct peers on record are Alexion (AstraZeneca Rare Disease), BioMarin Pharmaceutical, Vertex Pharmaceuticals and Regeneron Pharmaceuticals. Broad incumbents are Novartis, Roche, Pfizer, Takeda Pharmaceutical and Amgen. Ultragenyx Pharmaceutical is listed as an emerging player.
Does Sanofi Genzyme have an API?
No public API is recorded for Sanofi Genzyme.
What industry is Sanofi Genzyme in?
Sanofi Genzyme's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.